^
    3ms
    DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (clinicaltrials.gov)
    P2, N=180, Recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    DZD8586
    3ms
    DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) (clinicaltrials.gov)
    P2, N=155, Recruiting, Dizal Pharmaceuticals
    New P2 trial
    |
    DZD8586
    4ms
    TAI-SHAN5: DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=230, Recruiting, Dizal Pharmaceuticals | Not yet recruiting --> Recruiting | N=20 --> 230
    Enrollment open • Enrollment change
    |
    DZD8586
    1year
    First Report of Phase 1 Studies of DZD8586, a BBB Penetrant LYN/BTK Dual Inhibitor, in Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL) (ASH 2023)
    Introduction Resistance to covalent (ibrutinib, acalabrutinib and zanubrutinib) and non-covalent BTK inhibitors (pirtobrutinib) is an emerging clinical challenge...Methods TAI-SHAN1 (NCT05844956; CTR20220558) and TAI-SHAN5 (NCT05824585) are phase 1 dose escalation and expansion studies in patients with r/r B-NHL...The combination of BBB penetration, dual inhibition of LYN/BTK and potential to overcome C481S mutant CLL and other covalent BTKi resistant lymphomas suggest this may be a useful agent. Updated data will be presented at the meeting.
    Clinical • P1 data
    |
    LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Jaypirca (pirtobrutinib) • DZD8586
    1year
    Preclinical Study of DZD8586, a Non-Covalent LYN/BTK Dual Inhibitor with Excellent BBB Penetration, for the Treatment of B-Cell Non-Hodgkin Lymphoma (B-NHL) (ASH 2023)
    TMD-8-IbruR cells carrying the C481S mutation were generated by stepwise induction of increasing concentrations of Ibrutinib...In cell lines expressing C481X and pirtobrutinib resistance mutations, DZD8586 demonstrated concentration dependent anti-proliferative effects, with similar GI50s among cells carrying different BTK mutations...The Kpuu,CSF of DZD8586 in rat and monkey were 1.2 and 1.3, respectively, suggesting its excellent BBB penetration in humans. Conclusion DZD8586 is a novel non-covalent LYN/BTK dual inhibitor, which could overcome resistance mutations to the approved covalent and non-covalent BTK inhibitors, and derive clinical benefit to patients with DLBCL and CNSL by blocking both BTK-dependent and BTK-independent signaling pathways with excellent BBB penetration.
    Preclinical
    |
    LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
    |
    BTK C481S • BTK mutation
    |
    Imbruvica (ibrutinib) • Jaypirca (pirtobrutinib) • DZD8586
    over1year
    A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=386, Recruiting, Dizal Pharmaceuticals
    New P1/2 trial
    |
    DZD8586